The U.S. Department of Justice filed a suit against SpineFrontier, alleging payment of kickbacks to spine surgeons to induce use of SpineFrontier surgical devices.
Biogennix received FDA 510(k) clearance to market Agilon™ moldable bone graft for use in posterolateral spine procedures when mixed with autograft.
Medacta received FDA 510(k) clearance to market the MectaLock All-Suture Anchor, MectaTap TI Suture Anchor and Mectafix CL Fixation Button with Continuous Loop.
DiscGenics completed enrollment in its Phase I/II first-in-human U.S. clinical study of injectable disc cell therapy to treat degenerative disc disease.
Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate, designed specifically for smaller voids in the foot and ankle.